Company Insmed Inc.
Description Complex of insulin-like growth factor-1 (IGF-1) and its principal binding protein, IGF binding protein 3 (IGFBP3)
Molecular Target Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221) ; Insulin-like growth factor (IGF) binding protein 3 (IGFBP3)
Mechanism of Action Insulin-like growth factor-1 (IGF-1) receptor agonist
Therapeutic Modality Biologic: Protein
Latest Stage of Development Phase II
Standard Indication Retinopathy of prematurity
Indication Details Treat retinopathy of prematurity (ROP)
For sure each month that passes the value for INSM goes higher. A take out today would probably garner 2x-3x the share price. By year end the share price should be much higher and maybe 11B may be too high but 6-7 B would surely be needed. Lewis is a master at this game and has past experience from his former company. He will make sure if INSM is bought it will be for max value.
jd, I still believe the Merck/IDIX buyout sets the bar for smaller BIOs with promising drugs. That was for $3.85B for a promising Hepatitus C pipeline. But there are many "players" in that market - though quite lucrative. What makes Insmed unique is it really will have the ONLY approved NTM drug/market for a period of time. Many more indications beyond that. The "market" does not understand NTM and the seriousness or prevalence globally (growing). So, even if this week there was a serious buyout offer (or has been for awhile after BT granted), I would see it at $4B which would equate to almost $100.shr. The valuation of the indications and patients would drive that and as we progress, the price increases. S,o why would a big Pharma wait? We shall see but I expected a PR this week saying something about at least a partnership or the FDA/EMA discussions.